Company Filing History:
Years Active: 2020-2023
Title: Rose A Dibella: Innovator in Monoclonal Antibodies
Introduction
Rose A Dibella is a prominent inventor based in West Roxbury, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, her work focuses on innovative solutions for treating inflammatory and autoimmune diseases.
Latest Patents
Dibella's latest patents include groundbreaking research on IP-10 antibodies and their uses. The invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity. These antibodies inhibit the binding of IP-10 to its receptor, as well as block IP-10-induced calcium flux and cell migration. Additionally, the invention encompasses nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods for expressing these antibodies. It also includes immunoconjugates, bispecific molecules, and pharmaceutical compositions that utilize the antibodies. The methods for inhibiting IP-10 activity using these antibodies are particularly relevant for treating various inflammatory and autoimmune diseases.
Career Highlights
Rose A Dibella is associated with Bristol-Myers Squibb Company, where she continues to advance her research and development efforts. Her work has been instrumental in the field of immunology, contributing to the understanding and treatment of complex diseases.
Collaborations
Dibella has collaborated with notable colleagues such as Mohan Srinivasan and Shrikant Deshpande. These partnerships have fostered innovation and have been crucial in the advancement of her research projects.
Conclusion
Rose A Dibella stands out as a key figure in the development of monoclonal antibodies, with her innovative patents paving the way for new treatments in immunology. Her contributions to the field are invaluable and continue to impact the lives of many.